| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the School of Medicine, Departments of Medical Pathology and Laboratory Medicine (MIR, RG, and JWM), Neurology (DMM), and Nutrition (LHA), University of California, Davis, CA; the US Department of Agriculture, ARS Western Human Nutrition Research Center (LHA); the Department of Neuroscience, University of California, Berkeley, CA (WJJ); and the Department of Epidemiology, University of Michigan, Ann Arbor, MI (MNH)
2 Supported by NIH grants AG12975, AG10129, and AG10220; by USDA grant 00-35200-9073; and by an NIH Initiative for Minority Student Development fellowship (MIR). 3 Address reprint requests to JW Miller, UC Davis Medical Center, Department of Medical Pathology and Laboratory Medicine, Research 3, Room 3200A, 4645 Second Avenue, Sacramento, CA 95817. E-mail: jwmiller{at}ucdavis.edu.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Objective: We investigated whether folate status is associated with cognitive function and dementia in a cohort of elderly Latinos (aged 
60 y; n = 1789) exposed to folic acid fortification.
Design: Global cognitive function was assessed by the Modified Mini-Mental State Examination (3MSE) and specific cognitive functions by cross-culturally validated neuropsychological tests. Dementia was diagnosed according to the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 3rd edition revised, and California Alzheimer Disease Diagnostic and Treatment criteria. Red blood cell (RBC) folate was measured by automated chemiluminescence and total plasma homocysteine by HPLC.
Results: The prevalence of folate deficiency (RBC folate 
160 ng/mL) was <1%. After control for confounding by homocysteine, vitamin B-12, creatinine, demographic variables, and depressive symptom score, RBC folate was directly associated with 3MSE (P = 0.005) and delayed recall (P = 0.007) scores. In addition, adjusted odds ratios for low 3MSE score (78) and dementia diagnosis per unit increase in RBC folate were significantly below unity (P 0.008), which indicated that the relative risks of cognitive impairment and dementia decreased with increasing RBC folate concentration. In contrast, adjusted odds ratios for low 3MSE score and dementia diagnosis per unit increase in homocysteine were not significant.
Conclusion: RBC folate is directly associated with cognitive function scores and is inversely associated with dementia in elderly Latinos despite folic acid fortification.
Key Words: Folate • homocysteine • cognitive function • dementia • Modified Mini-Mental State Examination • vitamin B-12 • creatinine • Center for Epidemiologic Studies Depression scale • elderly • aging • Latinos
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The role of folate in homocysteine metabolism is fundamentally important. Folate is required for the biochemical conversion of homocysteine to methionine and the subsequent synthesis of S-adenosylmethionine (SAM). S-Adenosylhomocysteine, a product of SAM-dependent methylation reactions, subsequently loses its adenosyl group to form homocysteine. Homocysteine can then enter a new cycle of methionine synthesis and methylation, or it can be catabolized through cystathionine synthesis. Elevated plasma homocysteine is one of the primary consequences of folate deficiency. Furthermore, older people with low folate status are at a higher risk of cognitive impairment, dementia, and Alzheimer disease (6, 11–16), and it has been postulated that the effect of folate deficiency on brain function is mediated by homocysteine. However, several studies found that the association between low folate status and cognitive impairment, dementia, or Alzheimer disease remains significant after controlling for confounding by homocysteine, thus suggesting that folate may affect brain function through mechanisms not directly related to hyperhomocysteinemia (6, 11–16).
In January 1998, the US government mandated the fortification of grains (eg, cereals, breads) with folic acid to lower the incidence of neural tube birth defects (eg, spina bifida, anencephaly). The program of folic acid fortification has been successful in reducing both the prevalence of folate deficiency and hyperhomocysteinemia in the general population (17, 18) and the incidence of neural tube birth defects (19). Because of its success, we investigated whether folate status is associated with cognitive function scores and dementia diagnosis in a cohort of older adults exposed to folic acid fortification. We addressed this issue in a cross-sectional analysis of data from the Sacramento Area Latino Study on Aging (SALSA), a community-based cohort study of physical and cognitive functioning in elderly Latinos (age 60 y).
|
SUBJECTS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
60 y), residing in Sacramento, CA, and surrounding northern California communities, were recruited during a period of 1.5 y, beginning in February 1998 (ie, after the initiation of folic acid fortification). Subjects were considered "Latino" if they, their parents, or their grandparents were born in Mexico, Central America, or South America. The details of sampling and recruitment are described elsewhere (20). The study was approved by the University of California Davis Institutional Review Board, and informed consent was obtained from all subjects.
Sample collection and analyses
Fasting blood was collected from each participant during home visits and transported on ice to the University of California Davis Medical Center Clinical Laboratory for processing within 4 h of collection. Red blood cell (RBC) folate was measured on fresh, never frozen, blood by an automated chemiluminescence assay [ACS 180; Chiron Diagnostics (now Bayer Diagnostics), Tarrytown, NY]. Plasma and serum were isolated and stored at –80°C until analysis of vitamin B-12, homocysteine, and creatinine. Plasma vitamin B-12 was measured by radioassay (Quantaphase II; BioRad Diagnostics, Hercules, CA). Plasma homocysteine was measured by HPLC with postcolumn fluorescence detection (21). Serum creatinine was measured by standard spectrophotometric assay.
Neuropsychological assessment instruments
Both global and specific subdomains of cognitive function were assessed by using 7 neuropsychological instruments and have been previously described (10, 22). Briefly, the 3MSE (23), which evaluates memory, orientation, attention, and language on a scale of 0–100, was used to determine global cognitive ability. The delayed recall test, based on a 15-point scale, was used to assess the ability to learn and recall verbal information (10, 22). The 3MSE and delayed recall instruments were administered to all but 10 subjects (n = 1779). The other 5 neuropsychological instruments included object naming, picture association, verbal conceptual thinking, verbal attention span, and pattern recognition, each assessed on a 20-point scale (10, 22). These cognitive subdomain tests were administered to a subgroup of the total population (n = 537) consisting of a random sample of 20% of the total population, as well as all subjects not in the 20% random sample who scored below the 20th percentile on either the 3MSE or the delayed-recall instruments. Subjects were given the choice of taking the neuropsychological tests in English or Spanish.
Dementia diagnosis and assessment of depressive symptoms
Dementia diagnoses were established on the basis of neuropsychological test scores, mental status examination, the Informant Questionnaire on Cognitive Decline in the Elderly (24), medical history, and findings from a neurologic examination. Dementia was diagnosed based on American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 3rd edition revised, (25) criteria for dementia and the dementia criteria incorporated in the California Alzheimer Disease Diagnostic and Treatment Criteria for ischemic vascular dementia (26). Cognitive impairment with no dementia (CIND) was diagnosed if the person did not meet diagnostic criteria for dementia but had clinically significant impairment in 1 cognitive domain. Complete details of the diagnosis of dementia have been described in a previous publication (24). The Center for Epidemiologic Studies Depression (CES-D) scale was used to assess the presence of depressive symptoms on a scale of 0–60 points. A score of 16 is considered indicative of significant depressive symptoms (27).
Demographic data
Age, sex, and the number of years of education were recorded for each subject. An acculturation score was determined by using the Acculturation Rating Scale for Mexican Americans-II (28), on a scale of 0–37 points.
Statistical analysis
Multiple linear regression analyses were used to build 4 statistical models to describe the associations between RBC folate concentration (independent variable) and each of the cognitive function test instruments (dependent variables) before (model 1) and after adjustment for confounding by homocysteine alone (model 2), by homocysteine plus vitamin B-12 and creatinine (model 3), and by homocysteine plus vitamin B-12, creatinine, demographic (ie, age, sex, education, and acculturation), and depressive symptom (CES-D) variables (model 4). In addition, potential interactions between RBC folate and homocysteine on cognitive function scores were assessed by analysis of variance. In secondary analyses, odds ratios (ORs) were evaluated as indicators of the strength and direction of the relation between RBC folate and homocysteine (as independent continuous variables) and low 3MSE score (78), low delayed recall score (6), and dementia diagnosis. ORs with 95% CIs were determined by logistic regression in unadjusted models and in adjusted models controlling for potential confounding by age, sex, education, acculturation, vitamin B-12, creatinine, and CES-D score.
Because the values for RBC folate, plasma homocysteine, plasma vitamin B-12, and serum creatinine were not normally distributed (ie, there was tailing toward higher values), these variables were natural log-transformed before analysis. Statistical significance was defined for all analyses as P < 0.05. The statistical analyses were performed by using STATVIEW for MACINTOSH and WINDOWS (version 5.0.1; Abacus Concept, Berkeley, CA).
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. We found that <1% of the population had RBC folate concentrations below the cutoff for deficiency (160 ng/mL), consistent with the government-mandated fortification of flour with folic acid. A large proportion (17%) had elevated plasma homocysteine (13 µmol/L) despite folic acid fortification. Cognitive function scores indicative of significant cognitive impairment (3MSE 78, delayed recall 6) were observed in 22–25% of the population. The prevalence of dementia was 3.9% (n = 70), and an additional 3.8% (n = 68) were diagnosed with CIND (24).
|
. Before adjustment for confounding by homocysteine, vitamin B-12, creatinine, demographic and depressive symptom variables (Table 2, model 1), RBC folate was inversely correlated with all 7 cognitive function tests (P 0.004). The R2 values for these simple regressions indicate that RBC folate explains 1.6–3.2% (R2 = 0.016–0.032) of the variance in cognitive function scores within the sample. RBC folate remained inversely correlated with 6 cognitive function tests after the addition of homocysteine to the model (Table 2, model 2). The addition of vitamin B-12 and creatinine to the model had little influence on the associations between RBC folate and the cognitive function tests (Table 2, model 3). In contrast, the addition of the demographic variables (age, sex, education, acculturation) and CES-D score to the model significantly attenuated the associations between RBC folate and the cognitive function tests (Table 2, model 4), such that only the 3MSE and delayed recall tests remained significantly associated with RBC folate. The confounding variables that caused the greatest attenuation of the associations between RBC folate and the cognitive function tests were education and acculturation. For each analysis, the correlation coefficients for RBC folate were reduced in model 4 compared with models 1, 2, and 3, whereas R2 values in model 4 were 4- to 5-fold those in model 3. These R2 values indicate that the demographic and CES-D variables explain a much higher proportion of the variance in cognitive function scores than do the biochemical variables (folate, homocysteine, vitamin B-12, and creatinine). In addition, as indicated by analysis of variance, the associations among RBC folate and 3MSE and delayed recall scores were not modified by the interaction of RBC folate with homocysteine, and the interaction among these factors was not significant (data not shown).
|
, model 1), ORs for low 3MSE score (78), low delayed recall score (6), and dementia diagnosis were below unity and were statistically significant (P 0.003), indicating that the relative risks (RRs) of cognitive impairment and dementia decreased with increasing RBC folate concentration. After adjustment for homocysteine alone (Table 3, model 2) and for homocysteine plus the other confounding variables (Table 3, model 3), the ORs for low 3MSE score and dementia diagnosis remained significant (P 0.036), whereas the OR for low delayed recall score was not significant. No significant association was observed between RBC folate and diagnosis of CIND (data not shown).
|
, model 1) and in the models adjusted for RBC folate alone (Table 4, model 2), ORs for low 3MSE score, low delayed recall score, and dementia diagnosis were above unity and were statistically significant (P 0.002), indicating that the RRs of cognitive impairment and dementia increased with elevated homocysteine concentration. However, after controlling for RBC folate plus the other confounding variables (Table 4, model 3), the ORs for low cognitive function scores and dementia diagnosis were not significant. As for low cognitive function scores and dementia diagnosis, the ORs for CIND diagnosis were significant for the unadjusted model and the model adjusted for RBC folate alone but not for the model adjusted for RBC folate plus all the other confounding variables (data not shown).
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
A limitation of this study is that the cross-sectional design precludes determination of cause and effect. It is possible that cognitive impairment and dementia could negatively affect dietary intake and thus folate status. Arguing against this possibility is the very low prevalence of folate deficiency (<1%), consistent with a population that is receiving the benefits of folic acid fortification. Of interest will be how baseline folate status affects incident cognitive dysfunction and dementia in the SALSA population. The possible effect of confounding is another potential limitation of the study. The confounding factors that we controlled for in the statistical analyses were chosen a priori to be consistent with our previous publication on homocysteine and cognitive function in this population (10). However, it is possible that other confounding factors, such as vascular disease, medications, and lifestyle habits (eg, smoking, alcohol consumption), could have influenced the results.
In our previous publication in the SALSA study on homocysteine and cognitive function (10), we reported that homocysteine was inversely associated with both RBC folate and several cognitive function tests, including 3MSE, picture association, verbal attention, and pattern recognition. The associations between homocysteine and the cognitive function tests remained significant after controlling for confounding by RBC folate. In contrast, the present analysis indicates that RBC folate is associated with 3MSE and delayed recall scores but not with picture association, verbal attention, and pattern recognition. In addition, homocysteine was not associated with a diagnosis of dementia. These results are consistent with the findings of Riggs et al (6) who found that folate status was more strongly correlated than plasma homocysteine with delayed recall scores in the Boston Normative Aging study (men aged 54–81 y; n = 70). These findings suggest that despite that folate is a determinant of homocysteine, low folate status and hyperhomocysteinemia may have differential effects on discrete cognitive domains and discrete regions of the brain.
This raises the issue of mechanisms by which folate and homocysteine may affect brain function. Hyperhomocysteinemia is a risk factor for cerebrovascular disease (1) and has been shown to predict incident dementia in the Framingham study cohort (30). More basic research has indicated that homocysteine induces excitotoxic effects in brain through increased glutamate receptor activation (31). Folate deficiency may affect the brain by reducing synthesis of SAM and thus inhibiting SAM-dependent methylation reactions. Such reactions include the synthesis and catabolism of many neurotransmitters, including dopamine, norepinephrine, adrenaline, and serotonin. Serotonin is of particular interest because deficiency of this neurotransmitter is associated with depression. Folate deficiency is also associated with depression (32), and we have previously shown that low plasma folate is associated with elevated depressive symptoms in women, but not men, in the SALSA study (33). Moreover, oral SAM has antidepressant effects (34). Because depression is a strong determinant of cognitive function in older adults, the association between low folate status and cognitive function may be related to SAM, serotonin synthesis, and depression. However, in the present study, RBC folate remained associated with cognitive function and dementia after controlling for depressive symptoms. These observations suggest that depression does not explain the observed associations between RBC folate and cognitive function. The issue of how low folate status and hyperhomocysteinemia influence brain function remains an important area of investigation.
The results of the present study are consistent with previous studies performed before folic acid fortification in the United States or in other countries without folic acid fortification (6, 11–16). Particularly relevant is the New Mexico Elder Health Survey, a cohort study of Hispanic and non-Hispanic white elderly ( 65 y; n = 783) (15). Subjects with serum folate < 11.1 nmol/L had lower mean scores for global cognitive function and several tests of memory than did subjects with serum folate 11.1 nmol/L. Quadri et al (11) assessed a cohort of elderly subjects ( 60 y) seen at a memory clinic in Switzerland (n = 228). Subjects with mild cognitive impairment (n = 81) or dementia (n = 92) had significantly lower mean serum folate concentrations than control subjects without cognitive impairment (n = 55). Furthermore, those subjects in the lowest tertile of serum folate (<13.5 nmol/L) had an adjusted OR of 3.8 (95% CI: 1.3, 11.2) for dementia compared with the highest tertile of serum folate (>19.5 nmol/L) (P = 0.018). In a multicenter Canadian study of institutionalized and noninstitutionalized elderly (65 y; n = 1171), Ebly et al (14) found that there was a higher percentage of subjects with dementia in the lowest quartile of serum folate (10 nmol/L) compared with the highest quartile (>14 nmol/L) (P < 0.0001, chi-square test). Moreover, the mean 3MSE score for the subjects in the lowest quartile of serum folate was significantly lower than for subjects in the highest quartile (62.9 compared with 70.4, respectively; P = 0.003).
The finding that low folate status is associated with poor cognitive function and dementia, despite folic acid fortification, may lead some to conclude that more folic acid should be added to the food supply or, alternatively, that older adults should be encouraged to take folic acid supplements to reduce the risk of cognitive impairment and dementia. However, we caution that this conclusion may be premature. Cognitive impairment and dementia are pathologic processes that typically develop over years or even decades. Although this cross-sectional study was conducted in a population currently exposed to folic acid fortification, this exposure began within 1.5 y before the collection of blood samples and assessments of cognitive function. Folate status may have influenced the development of cognitive impairment and dementia in the years before folic acid fortification. The relation between current folate status in this population and prefortification status is unknown, although fortification has certainly shifted the distribution of RBC folate concentrations to higher values. It can be hypothesized that individuals who had low (ie, deficient) folate status before fortification remain in the low end of the current distribution of folate concentrations, even though most of these subjects are not currently folate deficient. If this is the case, then it would be expected that those subjects in the low end of the current distribution would have a greater RR of having low cognitive function scores and dementia than those subjects in the high end of the distribution, as was observed. Also, cognitive impairment caused by folate deficiency may become irreversible if the deficiency is prolonged. Therefore, folate status may improve with fortification but have no effect on cognitive function. What remains to be determined is the effect of the current amount of folic acid fortification on incident cognitive impairment and dementia in longitudinal studies of older adults.
Additionally, the elderly population in general, as well as the particular demographic group in whom this study was conducted (35), has a high prevalence of vitamin B-12 deficiency. The current high intake of folic acid by the population as a whole, and the elderly in particular, may be masking vitamin B-12 deficiency by attenuating hematologic evidence of the deficiency, that is, normalizing mean corpuscular volume and hemoglobin concentration. Therefore, further increasing the amount of folic acid in the food supply or recommending supplements may be premature.
|
ACKNOWLEDGMENTS |
|---|
MIR participated in the statistical analysis and interpretation of the data and was responsible for drafting the article with JWM. LHA (principal investigator of USDA grant 00-35200-9073) participated in the concept and design of the study and provided input into the final draft of the article. DMM (principal investigator of NIH grant AG10220) was responsible for the development of several of the cognitive function tests used in the study and provided input into the final draft of the article. WJJ (principal investigator of NIH grant AG10129) participated in the concept and design of the study and provided input into the final draft of the article. MNH (principal investigator of the SALSA study, NIH grant AG12975) participated in the concept and design of the study; was responsible for recruitment of study subjects, acquisition of blood samples, data collection, and data management; participated in the statistical analysis and interpretation of the data; and provided input into the final draft of the article. RG participated in the concept and design of the study and provided input into the final draft of the article. JWM participated in the concept and design of the study, supervised blood processing and biochemical analyses, participated in the statistical analysis and interpretation of the data, and was responsible for drafting the article with MIR. None of the authors had a conflict of interest in relation to this study.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  A. M. Troen, W.-H. Chao, N. A. Crivello, K. E. D'Anci, B. Shukitt-Hale, D. E. Smith, J. Selhub, and I. H. Rosenberg Cognitive Impairment in Folate-Deficient Rats Corresponds to Depleted Brain Phosphatidylcholine and Is Prevented by Dietary Methionine without Lowering Plasma Homocysteine J. Nutr., December 1, 2008; 138(12): 2502 - 2509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Clarke and D. A. Bennett B Vitamins for Prevention of Cognitive Decline: Insufficient Evidence to Justify Treatment JAMA, October 15, 2008; 300(15): 1819 - 1821. [Full Text] [PDF]
|
|
|
|
 |
|
 J-M Kim, R Stewart, S-W Kim, I-S Shin, S-J Yang, H-Y Shin, and J-S Yoon Changes in folate, vitamin B12 and homocysteine associated with incident dementia J. Neurol. Neurosurg. Psychiatry, August 1, 2008; 79(8): 864 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Garrod, R. Green, L. H. Allen, D. M. Mungas, W. J. Jagust, M. N. Haan, and J. W. Miller Fraction of Total Plasma Vitamin B12 Bound to Transcobalamin Correlates with Cognitive Function in Elderly Latinos with Depressive Symptoms Clin. Chem., July 1, 2008; 54(7): 1210 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hung, C. M. Abratte, W. Wang, R. Li, D. J. Moriarty, and M. A. Caudill Ethnicity and Folate Influence Choline Status in Young Women Consuming Controlled Nutrient Intakes J. Am. Coll. Nutr., April 1, 2008; 27(2): 253 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Selhub, M. S. Morris, and P. F. Jacques In vitamin B12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations PNAS, December 11, 2007; 104(50): 19995 - 20000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. de Lau, H. Refsum, A D. Smith, C. Johnston, and M. M. Breteler Plasma folate concentration and cognitive performance: Rotterdam Scan Study Am. J. Clinical Nutrition, September 1, 2007; 86(3): 728 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. T. Akbaraly, H. Faure, V. Gourlet, A. Favier, and C. Berr Plasma Carotenoid Levels and Cognitive Performance in an Elderly Population: Results of the EVA Study J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2007; 62(3): 308 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N Haan, J. W Miller, A. E Aiello, R. A Whitmer, W. J Jagust, D. M Mungas, L. H Allen, and R. Green Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging Am. J. Clinical Nutrition, February 1, 2007; 85(2): 511 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D. Smith Folic acid fortification: the good, the bad, and the puzzle of vitamin B-12 Am. J. Clinical Nutrition, January 1, 2007; 85(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Morris, P. F Jacques, I. H Rosenberg, and J. Selhub Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification Am. J. Clinical Nutrition, January 1, 2007; 85(1): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. McCracken, P. Hudson, R. Ellis, A. McCaddon, and the Medical Research Council Cognitive Function an Methylmalonic acid and cognitive function in the Medical Research Council Cognitive Function and Ageing Study Am. J. Clinical Nutrition, December 1, 2006; 84(6): 1406 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Feng, T.-P. Ng, L. Chuah, M. Niti, and E.-H. Kua Homocysteine, folate, and vitamin B-12 and cognitive performance in older Chinese adults: findings from the Singapore Longitudinal Ageing Study Am. J. Clinical Nutrition, December 1, 2006; 84(6): 1506 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Smith, S. A. Mathews Oliver, S. R. Zwart, G. Kala, P. A. Kelly, J. S. Goodwin, and C. B. Dyer Nutritional Status Is Altered in the Self-Neglecting Elderly J. Nutr., October 1, 2006; 136(10): 2534 - 2541. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
